Teleflex Inc Stock Price, News & Analysis

Teleflex Incorporated (NYSE: TFX) has announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. Located in Research Triangle, North Carolina, TCAP is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. The center aims to be a resource for patients, physicians, and healthcare organizations through education and partnerships with infection prevention professionals.

TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically central line-associated bloodstream infections (CLABSI). Teleflex's Arrow™ Brand of Vascular Access Products offers a comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against various pathogens. The company also provides Arrow™ Maximal Barrier Kitting options to protect patients and improve procedural efficiency for clinicians.

Teleflex Incorporated (NYSE:TFX) has announced its upcoming second quarter 2024 earnings conference call, scheduled for Thursday, August 1, 2024, at 8:00 a.m. Eastern Time. The call will provide an opportunity for the company to discuss its financial results and offer an operational update. Interested parties can pre-register to receive dial-in information or access the call via a live audio webcast on the Teleflex website. An audio replay will be available from 11:00 am Eastern Time on the same day, accessible through the website or by phone using specific dial-in numbers and a conference ID.

Teleflex Incorporated (TFX) has released its 2023 Global Impact Report, showcasing achievements and outlining goals for its Corporate Social Responsibility (CSR) program. The report aligns with leading sustainability standards and emphasizes the company's commitment to social, environmental, and ethical initiatives. Key highlights include validation of net-zero greenhouse gas emissions by 2050, improved ESG ratings, renewable energy generation at manufacturing sites, and substantial research grants. The report reflects Teleflex's dedication to sustainability, stakeholder engagement, and environmental stewardship.

Teleflex Incorporated (TFX) has expanded its intraosseous vascular access portfolio with the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray, the first FDA-cleared sterile, single-use IO tray in the market. This new tray includes a battery-powered driver and essential components for the IO access procedure, improving clinician workflow and patient care. The tray addresses the need for fast and precise vascular access, especially in time-critical situations where intravenous access is challenging. The development of this tray showcases Teleflex's commitment to innovation and empowering healthcare professionals.

Teleflex Incorporated presented new research findings at the American Urological Association Annual Meeting showcasing superior patient experience with the UroLift™ System for BPH. The studies demonstrated better symptom relief, quality of life improvements, and patient satisfaction compared to medication and other therapies. The UroLift™ System was found to provide rapid relief and durable outcomes with preservation of sexual function.

Teleflex Incorporated (TFX) declared a quarterly cash dividend of $0.34 per share for its common stock, payable on June 14, 2024, to shareholders of record on May 15, 2024.

Teleflex Incorporated reported first quarter financial results with revenues of $737.8 million, up 3.8% YoY, and GAAP diluted EPS of $0.33. The company lowered its GAAP revenue growth guidance to 3.35%-4.35% but raised its adjusted EPS guidance. Net revenue by segment showed growth in EMEA and OEM, while net revenue by global product category saw growth in Interventional and OEM. Other financial highlights included increases in cash, accounts receivable, and inventories. The company's outlook for 2024 includes lower revenue growth on a GAAP basis but higher diluted EPS. Non-GAAP financial measures were used to assess performance, with adjustments made for restructuring, acquisition, and integration expenses.

Teleflex Incorporated (NYSE: TFX) announced multiple clinical studies at the 2024 American Urological Association Annual Meeting, showcasing the UroLift™ System to treat benign prostatic hyperplasia. The studies include head-to-head RCT data presentations, post-surgery medication use analysis, and real-world evidence studies.

Teleflex Incorporated has announced the market release of the Wattson™ Temporary Pacing Guidewire, expanding its structural heart portfolio. The device offers dual functionality, supporting valve delivery and ventricular pacing during procedures like TAVR and BAV. Designed to reduce complications, costs, and procedural steps associated with traditional pacing methods, the guidewire aims to enhance procedural efficiency and safety.